Yuanyang Zhao Yuxing Chen Huaying Huang Xi Li Lin Shao Hao Ding
10.2147/OTT.S300556
Onco Targets Ther
2021 May 7;14:3063-3067.
egfr-mutant nsclc tki afatinib apatinib
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/33994798/
Case Reports
PMC8114361
33994798
Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
2021